NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Forecast, Price & News $2.32 -0.05 (-2.11%) (As of 05/26/2023 08:46 PM ET) Add Compare Share Share Today's Range$2.31▼$2.4050-Day Range$2.32▼$58.3252-Week Range$2.29▼$220.80Volume28,400 shsAverage Volume1.63 million shsMarket Capitalization$2.97 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ensysce Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside546.6% Upside$15.00 Price TargetShort InterestBearish11.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$44,235 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($13.00) to ($15.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Ensysce Biosciences has a forecasted upside of 546.6% from its current price of $2.32.Amount of Analyst CoverageEnsysce Biosciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.03% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently increased by 43.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENSC. Previous Next 1.9 News and Social Media Coverage News SentimentEnsysce Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ensysce Biosciences this week, compared to 2 articles on an average week.Search Interest8 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,235.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.40% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ensysce Biosciences are expected to decrease in the coming year, from ($13.00) to ($15.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Ensysce Biosciences (NASDAQ:ENSC) StockEnsysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.Read More Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENSC Stock News HeadlinesMay 16, 2023 | finance.yahoo.comENSC: ENSC Provides an Attractive Entry PointMay 15, 2023 | finance.yahoo.comEnsysce Biosciences Reports First Quarter 2023 Financial ResultsMay 30, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 12, 2023 | finance.yahoo.comEnsysce Biosciences, Inc. Announces Closing of $7 Million Public OfferingMay 10, 2023 | msn.comEnsysce Biosciences down 12%, prices $7M offeringMay 10, 2023 | finance.yahoo.comEnsysce Biosciences, Inc. Announces Pricing of $7 Million Public OfferingMay 9, 2023 | msn.comENSC: ENSC Announces Potential Game-Changing ResultsMay 9, 2023 | finance.yahoo.comWhy Are Ensysce Biosciences Shares Are Trading Higher TodayMay 30, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 9, 2023 | investorplace.comWhy Is Ensysce Biosciences (ENSC) Stock Up 50% Today?May 9, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose ProtectionMay 9, 2023 | finance.yahoo.comEnsysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose ProtectionApril 19, 2023 | finance.yahoo.comEnsysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated DevelopmentApril 15, 2023 | americanbankingnews.comEnsysce Biosciences (NASDAQ:ENSC) PT Lowered to $15.00 at Lake Street CapitalApril 11, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations WebsiteApril 11, 2023 | finance.yahoo.comEnsysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations WebsiteApril 9, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Ensysce Biosciences, Inc. (NASDAQ:ENSC) Increased by AnalystApril 5, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614April 3, 2023 | finance.yahoo.comENSC: Ensysce Provides Positive Result on Non-Addictive OpioidApril 3, 2023 | msn.comEnsysce stock jumps ~10% after pain drug PF614 meets key goal in trialApril 3, 2023 | finance.yahoo.comEnsysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614April 3, 2023 | americanbankingnews.comAltimmune (NASDAQ:ALT) & Ensysce Biosciences (NASDAQ:ENSC) Head to Head SurveyApril 2, 2023 | benzinga.comEnsysce Biosciences Inc Down 25.05% To $5.09 After Earnings BeatMarch 30, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 30, 2023 | finance.yahoo.comEnsysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 24, 2023 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection StudyMarch 22, 2023 | finance.yahoo.comEnsysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENSC Company Calendar Today5/30/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+546.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($139.5350) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,170,000.00 Net Margins-944.85% Pretax Margin-938.73% Return on EquityN/A Return on Assets-577.27% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$2.52 million Price / Sales1.18 Cash FlowN/A Price / Cash FlowN/A Book Value($7.54) per share Price / Book-0.31Miscellaneous Outstanding Shares1,280,000Free Float779,000Market Cap$2.97 million OptionableNot Optionable Beta0.58 Key ExecutivesDr. D. Lynn Kirkpatrick Ph.D. (Age 65)Pres, CEO & Director Comp: $288.15kMr. David C. Humphrey CPA (Age 54)CFO, Sec. & Treasurer Comp: $308.41kMr. Geoffrey Birkett (Age 60)Chief Commercial Officer Comp: $135kDr. Jeffrey Millard Ph.d. (Age 47)Chief Operating Officer Mr. Richard Wright M.B.A. (Age 50)MSE, Chief Bus. Officer Dr. William K. Schmidt Ph.D. (Age 71)Chairman of Clinical Advisory Board & Chief Medical Officer Dr. Linda Pestano Ph.D. (Age 53)Chief Devel. Officer More ExecutivesKey CompetitorsCelyad OncologyNASDAQ:CYADChina PharmaNYSE:CPHIGRI BioNASDAQ:GRISalarius PharmaceuticalsNASDAQ:SLRXNeptune Wellness SolutionsNASDAQ:NEPTView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 13,433 shares on 5/1/2023Ownership: 1.049%Bob G GowerBought 7,523 shares on 3/2/2023Total: $44,235.24 ($5.88/share)View All Insider TransactionsView All Institutional Transactions ENSC Stock - Frequently Asked Questions Should I buy or sell Ensysce Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares. View ENSC analyst ratings or view top-rated stocks. What is Ensysce Biosciences' stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for Ensysce Biosciences' stock. Their ENSC share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 546.6% from the stock's current price. View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts. How have ENSC shares performed in 2023? Ensysce Biosciences' stock was trading at $9.00 at the beginning of the year. Since then, ENSC stock has decreased by 74.2% and is now trading at $2.32. View the best growth stocks for 2023 here. Are investors shorting Ensysce Biosciences? Ensysce Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 113,600 shares, an increase of 43.8% from the April 30th total of 79,000 shares. Based on an average daily volume of 664,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 11.0% of the shares of the company are sold short. View Ensysce Biosciences' Short Interest. When is Ensysce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ENSC earnings forecast. When did Ensysce Biosciences' stock split? Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Ensysce Biosciences' stock symbol? Ensysce Biosciences trades on the NASDAQ under the ticker symbol "ENSC." Who are Ensysce Biosciences' major shareholders? Ensysce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.05%). View institutional ownership trends. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ensysce Biosciences' stock price today? One share of ENSC stock can currently be purchased for approximately $2.32. How much money does Ensysce Biosciences make? Ensysce Biosciences (NASDAQ:ENSC) has a market capitalization of $2.97 million and generates $2.52 million in revenue each year. The company earns $-24,170,000.00 in net income (profit) each year or ($139.5350) on an earnings per share basis. How can I contact Ensysce Biosciences? Ensysce Biosciences' mailing address is 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107. The official website for the company is ensysce.com. The company can be reached via phone at 858-263-4196 or via email at shannon@mzgroup.us. This page (NASDAQ:ENSC) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.